CMS Proposes Major Increase in Reimbursement for Canaloplasty

The CMS has just announced a significant increase of almost 30% in reimbursement for canaloplasty to $2643 (in the ASC setting), with reimbursement for competitor devices largely unchanged. This will make canaloplasty even more appealing compared to stent-based procedures, as canaloplasty already receives better reimbursement than stents so the differential will become even larger. The proposed changes will be finalised early November, and implemented calendar year 2025, so another catalyst event to add to the list and something that should further sustain the sales momentum. This is very exciting news that provides additional clarity to the longer-term outlook. So far I have just seen this reported by analysts at Citi and Piper (they seem to get the info quicker than its released), but I will try to find the original CMS source.

SGHT is up 22% today on the news today, but considering it has been rallying the past few months I would say EYE could be in for an even bigger day.